PT2561860T - Dispositivo polimérico implantável para a libertação prolongada de buprenorfina - Google Patents

Dispositivo polimérico implantável para a libertação prolongada de buprenorfina

Info

Publication number
PT2561860T
PT2561860T PT121934350T PT12193435T PT2561860T PT 2561860 T PT2561860 T PT 2561860T PT 121934350 T PT121934350 T PT 121934350T PT 12193435 T PT12193435 T PT 12193435T PT 2561860 T PT2561860 T PT 2561860T
Authority
PT
Portugal
Prior art keywords
buprenorphine
sustained release
polymeric device
implantable polymeric
implantable
Prior art date
Application number
PT121934350T
Other languages
English (en)
Inventor
A Patel Rajesh
R Bucalo Louis
Original Assignee
Titan Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Titan Pharmaceuticals Inc filed Critical Titan Pharmaceuticals Inc
Publication of PT2561860T publication Critical patent/PT2561860T/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04—Macromolecular materials
    • A61L31/048—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/12—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L31/125—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00—Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/14—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L31/16—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Emergency Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Addiction (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Materials Engineering (AREA)
  • Composite Materials (AREA)
  • Molecular Biology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
PT121934350T 2002-05-31 2003-06-02 Dispositivo polimérico implantável para a libertação prolongada de buprenorfina PT2561860T (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US38473302P 2002-05-31 2002-05-31

Publications (1)

Publication Number Publication Date
PT2561860T true PT2561860T (pt) 2018-05-08

Family

ID=29712085

Family Applications (1)

Application Number Title Priority Date Filing Date
PT121934350T PT2561860T (pt) 2002-05-31 2003-06-02 Dispositivo polimérico implantável para a libertação prolongada de buprenorfina

Country Status (14)

Country Link
US (12) US7736665B2 (pt)
EP (2) EP1509182A4 (pt)
JP (1) JP4668611B2 (pt)
AU (2) AU2003240493B2 (pt)
CA (1) CA2487577C (pt)
CY (1) CY1120510T1 (pt)
DK (1) DK2561860T3 (pt)
ES (1) ES2665999T3 (pt)
HU (1) HUE039377T2 (pt)
MX (1) MXPA04011875A (pt)
NZ (1) NZ536965A (pt)
PT (1) PT2561860T (pt)
SI (1) SI2561860T1 (pt)
WO (1) WO2003101358A1 (pt)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
US20040001889A1 (en) 2002-06-25 2004-01-01 Guohua Chen Short duration depot formulations
ATE482695T1 (de) 2002-12-13 2010-10-15 Durect Corp Orale darreichungsform mit flüssigen hochviskosen trägersystemen
US20090093875A1 (en) * 2007-05-01 2009-04-09 Abbott Laboratories Drug eluting stents with prolonged local elution profiles with high local concentrations and low systemic concentrations
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
EP1768650B1 (en) * 2004-06-04 2008-07-16 Camurus Ab Liquid depot formulations
EP2594259A1 (en) 2004-08-04 2013-05-22 Brookwood Pharmaceuticals, Inc. Methods for manufacturing delivery devices and devices thereof
BRPI0515372B8 (pt) 2004-09-17 2021-05-25 Durect Corp composição líquida para fornecer anestesia local prolongada após administração a um indivíduo, e, uso de bupivacaína, acetato isobutirato de sacarose e álcool benzílico
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
US20070027105A1 (en) 2005-07-26 2007-02-01 Alza Corporation Peroxide removal from drug delivery vehicle
WO2007139744A2 (en) * 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst
CA2670821C (en) 2006-08-09 2012-05-15 Intarcia Therapeutics, Inc. Osmotic delivery systems and piston assemblies
PL2117521T3 (pl) 2006-11-03 2012-11-30 Durect Corp Transdermalne systemy dostarczania zawierające bupiwakainę
CA2683610C (en) 2007-04-23 2013-01-08 Intarcia Therapeutics, Inc. Suspension formulations of insulinotropic peptides and uses thereof
DE602007005939D1 (de) * 2007-07-10 2010-05-27 Clariant Finance Bvi Ltd Verfahren zum Messen von Oktanol-Wasser-Verteilungskoeffizienten von Tensiden
US8124601B2 (en) * 2007-11-21 2012-02-28 Bristol-Myers Squibb Company Compounds for the treatment of Hepatitis C
WO2009075782A1 (en) 2007-12-06 2009-06-18 Durect Corporation Methods useful for the treatment of pain, arthritic conditions, or inflammation associated with a chronic condition
CA2709712C (en) 2007-12-20 2016-05-10 Surmodics Pharmaceuticals, Inc. Process for preparing microparticles having a low residual solvent volume
WO2009102467A2 (en) 2008-02-13 2009-08-20 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
US20100260844A1 (en) 2008-11-03 2010-10-14 Scicinski Jan J Oral pharmaceutical dosage forms
JP5675820B2 (ja) * 2009-09-22 2015-02-25 エボニック コーポレイションＥｖｏｎｉｋ Ｃｏｒｐｏｒａｔｉｏｎ 様々な生物活性剤担持構成を有するインプラントデバイス
MX378797B (es) 2009-09-28 2025-03-10 Intarcia Therapeutics Inc Establecimiento y/o terminacion rapidos de suministro de estado estable sustancial de farmaco.
PL2547332T3 (pl) * 2010-03-16 2019-07-31 Titan Pharmaceuticals, Inc. Heterogeniczne wyroby wszczepialne do podaży leku
GB2513267B (en) 2010-06-08 2015-03-18 Rb Pharmaceuticals Ltd Injectable flowable composition comprising buprenorphine
US9272044B2 (en) 2010-06-08 2016-03-01 Indivior Uk Limited Injectable flowable composition buprenorphine
GB2481017B (en) 2010-06-08 2015-01-07 Rb Pharmaceuticals Ltd Microparticle buprenorphine suspension
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
US20120288551A1 (en) * 2011-05-10 2012-11-15 Antecip Bioventures Ii Llc Implantable Polymeric Device for Sustained Release of Sufentanil
ES2596215T3 (es) 2011-10-24 2017-01-05 Asana Biosciences, Llc Ciclohexilaminas
US9566241B2 (en) 2012-02-21 2017-02-14 Auburn University Buprenorphine nanoparticle composition and methods thereof
TWI522101B (zh) 2012-04-17 2016-02-21 普渡製藥有限合夥事業 處理由類鴉片引起之不利的藥效動力反應之系統和方法
PT2877155T (pt) 2012-07-26 2020-12-18 Camurus Ab Formulações de opioides
AU2013294915C1 (en) 2012-07-26 2019-11-21 Camurus Ab Opioid formulations
CA2905131A1 (en) 2013-03-15 2014-09-18 Durect Corporation Compositions with a rheological modifier to reduce dissolution variability
WO2015095128A1 (en) 2013-12-16 2015-06-25 Asana Biosciences, Llc P2x3 and/or p2x2/3 compounds and methods
GB201404139D0 (en) 2014-03-10 2014-04-23 Rb Pharmaceuticals Ltd Sustained release buprenorphine solution formulations
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
NZ731309A (en) 2014-11-07 2022-02-25 Indivior Uk Ltd Buprenorphine dosing regimens
CN113598842A (zh) 2015-06-03 2021-11-05 因塔西亚制药公司 植入物放置和移除系统
KR102574993B1 (ko) 2016-05-16 2023-09-06 인타르시아 세라퓨틱스 인코포레이티드 글루카곤-수용체 선택적 폴리펩티드 및 이들의 이용 방법
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20200316159A1 (en) * 2016-06-03 2020-10-08 Jt Pharmaceuticals, Inc. Sustained release compositions of kappa-opioid receptor agonist
US12274794B2 (en) 2016-07-06 2025-04-15 Orient Pharma Co., Ltd. Oral dosage form with drug composition, barrier layer and drug layer
US10174039B2 (en) 2016-09-30 2019-01-08 Asana Biosciences, Llc P2X3 and/or P2X2/3 compounds and methods
WO2018129058A1 (en) 2017-01-03 2018-07-12 Intarcia Therapeutics, Inc. Methods comprising continuous administration of a glp-1 receptor agonist and co-adminstration of a drug
US10646484B2 (en) 2017-06-16 2020-05-12 Indivior Uk Limited Methods to treat opioid use disorder
WO2019222856A1 (en) 2018-05-24 2019-11-28 Nureva Inc. Method, apparatus and computer-readable media to manage semi-constant (persistent) sound sources in microphone pickup/focus zones
WO2019226519A1 (en) 2018-05-24 2019-11-28 Celanese EVA Performance Polymers Corporation Implantable device for sustained release of a macromolecular drug compound
AU2019275406B2 (en) 2018-05-24 2024-11-14 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
USD933219S1 (en) 2018-07-13 2021-10-12 Intarcia Therapeutics, Inc. Implant removal tool and assembly
CA3167217A1 (en) 2020-01-13 2021-07-22 Durect Corporation Sustained release drug delivery systems with reduced impurities and related methods
CN116940358A (zh) 2021-01-12 2023-10-24 度勒科特公司 持续释放药物递送系统和有关的方法
WO2022231930A1 (en) 2021-04-26 2022-11-03 Celanese Eva Performance Polymers Llc Implantable device for sustained release of a macromolecular drug compound
WO2025174767A1 (en) * 2024-02-13 2025-08-21 Biraj Investments, Llc Highly loaded implantable devices with high tensile strength for drug delivery

Family Cites Families (114)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES335314A1 (es) * 1966-01-06 1967-12-01 Ceskoslovenska Akademie Ved Mejoras introducidas en la preparacion de vehiculos insolubles de sustancias al menos parcialmente solubles, biologicamente activas.
US3717639A (en) 1967-05-04 1973-02-20 Little Inc A Process for the preparation of 1-(2-nitro-3,4-di-lower-alkoxybenzyl)isoquinolines
US4069307A (en) 1970-10-01 1978-01-17 Alza Corporation Drug-delivery device comprising certain polymeric materials for controlled release of drug
US3814768A (en) 1971-11-26 1974-06-04 Lewenstein E 6-methylene-6-desoxy dihydro morphine and codeine derivatives and pharmaceutically acceptable salts
US4351337A (en) 1973-05-17 1982-09-28 Arthur D. Little, Inc. Biodegradable, implantable drug delivery device, and process for preparing and using the same
US4450150A (en) 1973-05-17 1984-05-22 Arthur D. Little, Inc. Biodegradable, implantable drug delivery depots, and method for preparing and using the same
US3923939A (en) * 1974-06-07 1975-12-02 Alza Corp Process for improving release kinetics of a monolithic drug delivery device
US4148871A (en) 1977-10-11 1979-04-10 Pitt Colin G Sustained subdermal delivery ofdrugs using poly(ε-caprolactone) and its copolymers
US4464378A (en) 1981-04-28 1984-08-07 University Of Kentucky Research Foundation Method of administering narcotic antagonists and analgesics and novel dosage forms containing same
US4543256A (en) 1982-03-17 1985-09-24 Northeastern University (-)-10,1L Methylenedioxy-N-N-propylnoraporphine and methods employing it for inhibiting the effects of epileptic seizures and for prevention and treatment of duodenal ulcers
AU8533582A (en) 1981-07-10 1984-01-12 Reckitt & Colman Products Limited Stable solutions of buprenorphine
US4725442A (en) 1983-06-17 1988-02-16 Haynes Duncan H Microdroplets of water-insoluble drugs and injectable formulations containing same
US4622219A (en) 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
US4535157A (en) 1983-11-01 1985-08-13 Key Pharmaceuticals, Inc. Process for making 6-desoxy-6-methylenenaloxone and 6-desoxy-6-methylenenaltrexone
US4818542A (en) 1983-11-14 1989-04-04 The University Of Kentucky Research Foundation Porous microspheres for drug delivery and methods for making same
GB8332556D0 (en) 1983-12-06 1984-01-11 Reckitt & Colmann Prod Ltd Analgesic compositions
US4599342A (en) 1984-01-16 1986-07-08 The Procter & Gamble Company Pharmaceutical products providing enhanced analgesia
FR2559780B1 (fr) 1984-02-21 1990-05-04 Tech Cuir Centre Systemes biocompatibles implantables a base de collagene permettant la conservation et/ou la culture cellulaires et/ou la liberation controlee de principes actifs
GB8430346D0 (en) 1984-11-30 1985-01-09 Reckitt & Colmann Prod Ltd Analgesic compositions
US4678809A (en) 1985-02-01 1987-07-07 Michael Phillips Injectable fomulations of disulfiram for the treatment of alcoholism
US4898733A (en) 1985-11-04 1990-02-06 International Minerals & Chemical Corp. Layered, compression molded device for the sustained release of a beneficial agent
US4692451A (en) 1985-12-11 1987-09-08 Trustees Of Tufts College Method for preventing stereotypic behavior in animals
DE3689650T2 (de) 1985-12-17 1994-05-26 United States Surgical Corp Bioresorbierbare Polymere von hohem Molekulargewicht und Implantate davon.
US5316759A (en) 1986-03-17 1994-05-31 Robert J. Schaap Agonist-antagonist combination to reduce the use of nicotine and other drugs
US4962091A (en) 1986-05-23 1990-10-09 Syntex (U.S.A.) Inc. Controlled release of macromolecular polypeptides
CH672888A5 (pt) * 1986-11-07 1990-01-15 Mepha Ag
JPS63122620A (ja) 1986-11-12 1988-05-26 Sanraku Inc ポリ乳酸マイクロスフエア及びその製造方法
US5718921A (en) 1987-03-13 1998-02-17 Massachusetts Institute Of Technology Microspheres comprising polymer and drug dispersed there within
US5601835A (en) * 1987-04-29 1997-02-11 Massachusetts Institute Of Technology Polymeric device for controlled drug delivery to the CNS
US4883666A (en) * 1987-04-29 1989-11-28 Massachusetts Institute Of Technology Controlled drug delivery system for treatment of neural disorders
US5114719A (en) * 1987-04-29 1992-05-19 Sabel Bernhard A Extended drug delivery of small, water-soluble molecules
US4861627A (en) 1987-05-01 1989-08-29 Massachusetts Institute Of Technology Preparation of multiwall polymeric microcapsules
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
ES2054784T3 (es) 1987-08-08 1994-08-16 Akzo Nv Un metodo para la fabricacion de un implante.
US5156844A (en) 1987-11-17 1992-10-20 Brown University Research Foundation Neurological therapy system
GB8728294D0 (en) 1987-12-03 1988-01-06 Reckitt & Colmann Prod Ltd Treatment compositions
US5002935A (en) 1987-12-30 1991-03-26 University Of Florida Improvements in redox systems for brain-targeted drug delivery
US4882335A (en) 1988-06-13 1989-11-21 Alko Limited Method for treating alcohol-drinking response
US5236714A (en) * 1988-11-01 1993-08-17 Alza Corporation Abusable substance dosage form having reduced abuse potential
JP2738881B2 (ja) 1989-06-21 1998-04-08 ブラウン ユニバーシティ リサーチ ファウンデイション 神経治療システム
US4968091A (en) * 1989-08-02 1990-11-06 Mariol John V Article useful as booster chair and as step stool
US5750136A (en) 1989-11-03 1998-05-12 Riker Laboratories, Inc. Bioadhesive composition and patch
US5240711A (en) 1989-11-29 1993-08-31 Lts Lohmann Therapie-Systeme Gmbh & Co. Kg Transdermal therapeutic system comprising as active component buprenorphine
US5075341A (en) 1989-12-01 1991-12-24 The Mclean Hospital Corporation Treatment for cocaine abuse
US5219858A (en) 1990-03-27 1993-06-15 Parnell Pharmaceuticals, Inc. Method and compositions for effecting withdrawal from drug dependency
EP0452111B1 (en) 1990-04-13 1998-07-15 Takeda Chemical Industries, Ltd. Biodegradable high-molecular polymers, production and use thereof
US5086058A (en) 1990-06-04 1992-02-04 Alko Ltd. Method for treating alcoholism with nalmefene
US5128145A (en) 1990-06-13 1992-07-07 Alza Corporation Dosage form for Parkinson's disease, spasticity and muscle spasms
US5069909A (en) 1990-06-20 1991-12-03 Cygnus Therapeutic Systems Transdermal administration of buprenorphine
US5114718A (en) 1990-09-20 1992-05-19 The Procter & Gamble Company Sustained release compositions for treating periodontol disease
US5486362A (en) 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5149538A (en) * 1991-06-14 1992-09-22 Warner-Lambert Company Misuse-resistive transdermal opioid dosage form
US5211951A (en) 1991-07-24 1993-05-18 Merck & Co., Inc. Process for the manufacture of bioerodible poly (orthoester)s and polyacetals
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
US5478577A (en) 1993-11-23 1995-12-26 Euroceltique, S.A. Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level
US5968551A (en) 1991-12-24 1999-10-19 Purdue Pharma L.P. Orally administrable opioid formulations having extended duration of effect
FR2695826B1 (fr) * 1992-09-21 1995-01-06 Theramex Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.
US5580876A (en) 1992-09-21 1996-12-03 Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists
US5298017A (en) * 1992-12-29 1994-03-29 Alza Corporation Layered electrotransport drug delivery system
DE69434304T2 (de) 1993-03-26 2005-12-29 Merkus, Franciscus Wilhelmus H.M. Pharmazeutische Zusammensetzungen zur intranasalen Verabreichung von Dihydroergotamin
US5503844A (en) * 1993-05-18 1996-04-02 Mli Acquisition Corp. Ii Foam laminate transdermal patch
GB9311132D0 (en) * 1993-05-28 1993-07-14 Eisai London Res Lab Ltd Control of cell death
US5650173A (en) 1993-11-19 1997-07-22 Alkermes Controlled Therapeutics Inc. Ii Preparation of biodegradable microparticles containing a biologically active agent
ATE288270T1 (de) 1993-11-19 2005-02-15 Janssen Pharmaceutica Nv Mikroverkapselte 1,2-benzazole
EP2283821A1 (en) 1993-11-19 2011-02-16 Alkermes, Inc. Preparation of biodegradable microparticles containing a biologically active agent
JP3720386B2 (ja) 1993-12-27 2005-11-24 住友製薬株式会社 薬物放出制御製剤
HUT75469A (en) 1994-02-28 1997-05-28 Medinova Med Consulting Gmbh Drug targeting system, method for preparing same and its use
CA2188385C (en) 1994-04-22 2000-07-11 Ragab El-Rashidy Dosage forms and method for ameliorating male erectile dysfunction
JP2819236B2 (ja) 1994-05-06 1998-10-30 日東電工株式会社 経皮吸収製剤
US5604198A (en) 1994-05-12 1997-02-18 Poduslo; Joseph F. Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents
US5633000A (en) * 1994-06-23 1997-05-27 Axxia Technologies Subcutaneous implant
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US6063116A (en) * 1994-10-26 2000-05-16 Medarex, Inc. Modulation of cell proliferation and wound healing
US5562917A (en) 1994-12-23 1996-10-08 Pentech Pharmaceuticals, Inc. Transdermal administration of apomorphine
DE69603577T2 (de) 1995-02-10 1999-11-25 Medtronic, Inc. Verfahren und vorrichtung zur verabreichung von analgetika
IL112834A (en) * 1995-03-01 2000-12-06 Yeda Res & Dev Pharmaceutical compositions for controlled release of soluble receptors
US5587381A (en) 1995-03-27 1996-12-24 Sinclair; John D. Method for terminating methadone maintenance through extinction of the opiate-taking responses
US5590876A (en) * 1995-04-03 1997-01-07 Hasbro, Inc. Ball tossing device
US5877224A (en) 1995-07-28 1999-03-02 Rutgers, The State University Of New Jersey Polymeric drug formulations
CA2182851A1 (en) * 1995-08-15 1997-02-16 August Masaru Watanabe Method for treating substance abuse withdrawal
US6004962A (en) 1995-09-11 1999-12-21 Gooberman; Lance L. Rapid opioid detoxification
US5733565A (en) * 1996-02-23 1998-03-31 The Population Council, Center For Biomedical Research Male contraceptive implant
US6004969A (en) 1996-04-15 1999-12-21 National Science Council Transdermal delivery of buprenorphine preparations
US6271240B1 (en) 1996-05-06 2001-08-07 David Lew Simon Methods for improved regulation of endogenous dopamine in prolonged treatment of opioid addicted individuals
US20040024006A1 (en) 1996-05-06 2004-02-05 Simon David Lew Opioid pharmaceutical compositions
US20030211157A1 (en) 1996-05-06 2003-11-13 Simon David Lew Semi-sol delivery blend for water soluble molecules
US5980948A (en) 1996-08-16 1999-11-09 Osteotech, Inc. Polyetherester copolymers as drug delivery matrices
US6203813B1 (en) 1997-01-13 2001-03-20 Lance L. Gooberman Pharmaceutical delivery device and method of preparation therefor
US20010036469A1 (en) 1997-01-13 2001-11-01 Gooberman Lance L. Opiate antagonist implant and process for preparation therefor
US5968547A (en) 1997-02-24 1999-10-19 Euro-Celtique, S.A. Method of providing sustained analgesia with buprenorphine
US5919473A (en) * 1997-05-12 1999-07-06 Elkhoury; George F. Methods and devices for delivering opioid analgesics to wounds via a subdermal implant
US6342250B1 (en) 1997-09-25 2002-01-29 Gel-Del Technologies, Inc. Drug delivery devices comprising biodegradable protein for the controlled release of pharmacologically active agents and method of making the drug delivery devices
CN1204890C (zh) 1997-12-22 2005-06-08 欧罗赛铁克股份有限公司 防止阿片样物质滥用的方法
TW460599B (en) 1998-01-14 2001-10-21 Toshiba Corp Method for forming fine wiring pattern
US6007841A (en) 1998-03-13 1999-12-28 Algos Pharmaceutical Corporation Analgesic composition and method for treating pain
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
EP0945133A1 (en) 1998-03-26 1999-09-29 Lipha Combination for the treatment of alcohol and drug dependence containing an opioid antagonist and a NMDA receptor complex modulator
US6001845A (en) 1998-06-19 1999-12-14 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US6011043A (en) 1998-06-19 2000-01-04 Schering Corporation Combination of phentolamine and apomorphine for the treatment of human sexual function and dysfunction
US5994363A (en) 1998-08-24 1999-11-30 Pentech Pharmaceuticals, Inc. Amelioration of apomorphine adverse effects
US6541021B1 (en) 1999-03-18 2003-04-01 Durect Corporation Devices and methods for pain management
KR100730440B1 (ko) 1999-08-27 2007-06-19 브룩우드 파마슈티컬스, 인코포레이티드 주사가능한 부프레노르핀 미세 입자 조성물 및 이의 용도
WO2001043726A1 (en) 1999-12-16 2001-06-21 Trident Technologies, Llc System and method for extended delivery of a therapeutic agent with its receptor loading dose
AU2002246490A1 (en) * 2000-10-12 2002-07-30 Pharmacia And Upjohn Company Method of treating parkinson's disease
CN1520297A (zh) 2001-04-26 2004-08-11 ���ߵ���Ƶϵͳ��˾ 包含复合药物(codrugs)的缓释药物传递系统
US20020198574A1 (en) 2001-06-22 2002-12-26 Ron Gumpert Automatic sobriety training and reconditioning system
CN1658836A (zh) 2002-05-07 2005-08-24 控制传输系统公司 形成药物传递装置的方法
PT2561860T (pt) * 2002-05-31 2018-05-08 Titan Pharmaceuticals Inc Dispositivo polimérico implantável para a libertação prolongada de buprenorfina
WO2004054553A1 (en) 2002-12-13 2004-07-01 Euro-Celtique S.A. Transdermal buprenorphine dosage regimen for analgesia
CA2520613C (en) 2003-03-31 2012-12-04 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of dopamine agonist
WO2004110400A2 (en) * 2003-05-30 2004-12-23 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of nalmefene
US20050245541A1 (en) 2004-03-19 2005-11-03 Elliot Ehrich Methods for treating alcoholism
WO2007139744A2 (en) 2006-05-23 2007-12-06 Titan Pharmaceuticals, Inc. Implantable polymeric device for sustained release of buprenorphine with minimal initial burst

Also Published As

Publication number Publication date
WO2003101358A1 (en) 2003-12-11
EP2561860A1 (en) 2013-02-27
AU2003240493A1 (en) 2003-12-19
CY1120510T1 (el) 2019-07-10
HUE039377T2 (hu) 2018-12-28
MXPA04011875A (es) 2005-03-31
US20140171457A1 (en) 2014-06-19
US7736665B2 (en) 2010-06-15
US20130171229A1 (en) 2013-07-04
SI2561860T1 (en) 2018-05-31
ES2665999T3 (es) 2018-04-30
US20190350842A1 (en) 2019-11-21
US20140161860A1 (en) 2014-06-12
US20140088131A1 (en) 2014-03-27
AU2008212011A1 (en) 2008-09-25
US20180177717A1 (en) 2018-06-28
US20220241186A1 (en) 2022-08-04
US20040033250A1 (en) 2004-02-19
CA2487577A1 (en) 2003-12-11
NZ536965A (en) 2007-02-23
US20080026031A1 (en) 2008-01-31
DK2561860T3 (en) 2018-04-30
JP4668611B2 (ja) 2011-04-13
AU2003240493B2 (en) 2008-06-12
US20210046000A1 (en) 2021-02-18
US20160367477A1 (en) 2016-12-22
CA2487577C (en) 2014-11-18
US20140163057A1 (en) 2014-06-12
EP2561860B1 (en) 2018-02-28
AU2008212011B2 (en) 2010-05-27
EP1509182A4 (en) 2009-12-30
JP2005528422A (ja) 2005-09-22
EP1509182A1 (en) 2005-03-02

Similar Documents

Publication Publication Date Title
EP1509182A4 (en) IMPLANTABLE POLYMERS DEVICE FOR THE DELAYED RELEASE OF BUPRENORPHINE
GB2399753B (en) Method of making a sustained release ophthalmological device
TWI347202B (en) Controlled release preparation
AU2003219024A1 (en) Implantable device
PL370635A1 (en) Hearing protection device
GB0218577D0 (en) Safety device
EP1556143A4 (en) RESCUE DEVICE
TW532713U (en) Retainer device
IL166344A0 (en) Device for tectile stimulation
EP1492508A4 (en) DOSAGE FORMS WITH CONTROLLED RELEASE
GB2388148B (en) Safety anchor device
AU2003300904A8 (en) Antagonists for human prolactin
GB0203332D0 (en) Medical device
EP1539140A4 (en) CARVEDILOLHYDOBROMID
HK1072709A (en) Implantable polymeric device for sustained release of buprenorphine
HK1086498A (en) Implantable polymeric device for sustained release of nalmefene
GB0204519D0 (en) Socket safety device
AU2003273839A1 (en) Automatic massage device
GB0214588D0 (en) Therapeutic device
ZA200308890B (en) Safety device
GB0222452D0 (en) Prosthetic device
PL353333A1 (en) Self-locking device
AU2002322414A8 (en) Quick release delineator apparatus
TW561899U (en) Highrise escape device
GB0208931D0 (en) Condom plus